Filing Details

Accession Number:
0001415889-24-030210
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-12-27 19:47:04
Reporting Period:
2024-12-26
Accepted Time:
2024-12-27 19:47:04
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1438533 Travere Therapeutics Inc. TVTX Pharmaceutical Preparations (2834) 262383102
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1882909 Sandra Calvin C/O Travere Therapeutics, Inc.
3611 Valley Centre Drive, Suite 300
San Diego CA 92130
Svp, Chief Accounting Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-12-26 15,000 $12.67 69,927 No 4 M Direct
Common Stock Disposition 2024-12-26 15,000 $17.22 54,927 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee stock option (right to buy) Disposition 2024-12-26 15,000 $0.00 15,000 $12.67
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2025-01-02 No 4 M Direct
Footnotes
  1. The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, adopted by the Reporting Person on September 9, 2024.
  2. The weighted average sale price for the transaction reported was $17.21856, and the range of prices were between $16.985 and $17.545. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
  3. The stock option is fully vested and exercisable.